Janssen Biotech gets option to Modern Biosciences' preclinical RA compounds
Modern Biosciences PLC licensed Janssen Biotech Inc. an option for exclusive rights to preclinical bone-protective compounds for rheumatoid arthritis.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.